CVAC vs JNJ

For growth investors, CureVac N.

V. (CVAC) is the stronger pick with 895. 5% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). CureVac N. V. (CVAC) offers the better valuation at 6. 5x trailing P/E, making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CureVac N.

V. (CVAC) is the cheapest at 6. 5x versus Johnson & Johnson at 38. 8x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.

0%, compared to -95. 0% for CureVac N. V. (CVAC). Over 10 years, the gap is even starker: JNJ returned +136. 2% versus CVAC's -91. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus CureVac N. V. 's 1. 23β — meaning CVAC is approximately 2064% more volatile than JNJ relative to the S&P 500. On balance sheet safety, CureVac N. V. (CVAC) carries a lower debt/equity ratio of 6% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CureVac N.

V. (CVAC) is pulling ahead at 895. 5% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: CureVac N. V. grew EPS 161. 0% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, CVAC leads at 73. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CureVac N.

V. (CVAC) is the more profitable company, earning 30. 3% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 30. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CVAC leads at 33. 2% versus 24. 9% for JNJ. At the gross margin level — before operating expenses — CVAC leads at 80. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CVAC: 350.

6% to $21. 00.

In this comparison, JNJ (2.

2% yield) pays a dividend. CVAC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, CVAC: -91. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CVAC is a small-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while CVAC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.